Cell/Gene Tx channel feed

In pur­suit of ac­ces­si­ble sick­le cell cure, No­var­tis inks $1.5B deal to tap Pre­ci­sion's AR­CUS gene edit­ing tech

3 years ago
Deals

Car­bon Bio­sciences emerges with a new vi­ral vec­tor to shake up the cys­tic fi­bro­sis gene ther­a­py field

3 years ago
Financing
Startups

Reg­u­lat­ing new re­gen­er­a­tive ther­a­pies: FDA kicks off the process of rec­og­niz­ing vol­un­tary stan­dards

3 years ago
FDA+

In­ter­view with the Broad In­sti­tute's David Liu: Is this the year base edit­ing makes its mark?

3 years ago

No­var­tis may still be grap­pling with Kym­ri­ah sales, but his­toric CAR-T promise still shines through 5-year da­ta

3 years ago
R&D
Pharma

Ho­mol­o­gy cleared to re­sume gene ther­a­py tri­al for rare meta­bol­ic dis­ease af­ter FDA lifts hold

3 years ago
R&D

Blue­bird goes 2-for-2 on gene ther­a­pies at FDA ad­comm with thumbs up for beti-cel

3 years ago
FDA+

Re­genxbio opens gene ther­a­py man­u­fac­tur­ing fa­cil­i­ty at its Mary­land HQ

3 years ago
Pharma
Manufacturing

Along­side tiny da­ta drop, Cari­bou plans dose es­ca­la­tion for its first off-the-shelf CAR-T tri­al

3 years ago
R&D

With deep ties to Bay­lor and fresh sup­port from Po­laris, Sin­ga­pore's Tes­sa rais­es $126M for piv­otal CAR study

3 years ago
Financing

With eyes on first al­lo­gene­ic CAR-T ap­proval, Pre­ci­sion touts 100% re­sponse in 's­mall niche' pop­u­la­tion

3 years ago
R&D

Ahead of 2-day ad­comm, FDA sounds pos­i­tive on one blue­bird gene ther­a­py but ques­tions re­main for an­oth­er

3 years ago
FDA+

ARCH-backed Re­silience nabs its lat­est fi­nanc­ing round, putting to­geth­er a mas­sive $625M Se­ries D

3 years ago
Financing
Manufacturing

#AS­CO22: Leg­end, J&J say Carvyk­ti holds up past the two-year mark as pair preps for po­ten­tial sec­ond nod

4 years ago
R&D
China

Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

4 years ago
Deals

Even at $2M+, ICER calls blue­bird's po­ten­tial gene ther­a­py for blood dis­or­der 'su­pe­ri­or' to stan­dard of care

4 years ago
Pharma

FDA's Pe­ter Marks lays out plans to sup­port gene ther­a­pies for ul­tra-rare dis­eases

4 years ago
FDA+

Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

4 years ago
R&D

Ahead of FDA, EMA rec­om­mends au­tho­riz­ing new gene ther­a­py treat­ment for ul­tra-rare dis­ease

4 years ago
R&D

Ather­sys tries to post-hoc-an­a­lyze its way out of an­oth­er tri­al fail for stroke stem cell ther­a­py

4 years ago
R&D

Scoop: Af­ter pulling IPO am­bi­tions last De­cem­ber, Jeff Aron­in's Cas­tle Creek turns to pri­vate back­ers

4 years ago
Financing

Tout­ing 100% OS rate in piv­otal rare dis­ease tri­al, Rock­et Phar­ma ready to head to FDA

4 years ago
R&D

Pfiz­er, Sarep­ta and two oth­ers sug­gest Duchenne drug safe­ty is­sues tied to "class ef­fect"

4 years ago
R&D

Af­ter lay­ing off a fourth of its staff, gene ther­a­py start­up Swan­Bio sees fresh fi­nanc­ing as it heads to­wards the clin­ic

4 years ago
Financing
First page Previous page 28293031323334 Next page Last page
A service from the Financial Times